At $475,000, is Novartis' Kymriah a bargain—or another example of skyrocketing prices?
admin 31st August 2017 Uncategorised 0Novartis won its FDA approval for CAR-T drug Kymriah on Wednesday, but questions about pricing, access and more are just beginning. The company priced its groundbreaking therapy at $475,000, short of some market forecasts, but out of control for others pushing for lower drug costs.
More: At 5,000, is Novartis' Kymriah a bargain—or another example of skyrocketing prices?
Source: fierce